GIO/Q
Finance awarness Quizz

What is GIO ambition by 2020?
Reduction of the opex by 20%
Reduction of the cost of sales by 20%
Increase of the volume by 10% year on year
Reduction of the cost per dose sold by 20%
What percentage of the final SPC is related to R&D?
0%
1-10%
11%-20%
21%-30%
The same material produced at two different production sites will have the same SPC...
True
False
Depreciation represents ..... % of the overall CGS (Cost of Good Sold)
0-5%
6-10%
11%-15%
16%-20%
For a vaccine costing €2/dose for a 1 dose presentation, how much does the cost per dose approx. Decrease for a two dose presentation?
2€ / dose
1,5€ / dose
1€ / dose
No change
GSK Vaccines has invested massively in fixed assets, what would you expect as an impact on Vaccines balance sheet and P&L?
Balance Sheet: decrease in the fixed asset
P&L: decrease in the operating profit in the short term
P&L: decrease of the depreciations
When is production recognized in the P&L as CGS (Cost of Good Sold)?
Once it is produced
Once it is sold
Once it is recognized in the Balance sheet
{"name":"GIO\/Q Finance awarness Quizz", "url":"https://www.quiz-maker.com/QPREVIEW","txt":"How did GSK Free Cash Flow evolved over last 5 years?, What are the components of the free cash flow?, According to you, what was the main reason of the decrease of the free cash flow?","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}
Powered by: Quiz Maker